The relationships among physiologic variables, quality of life, and fatigue in patients with multiple myeloma

Oncology Nursing Forum

Volumn 36, Issue 2, 2009, Pages 209-216

  Booker, Reanne ^a   Olson, Karin ^b   Pilarski, Linda M ^c   Noon, Joseph P ^d   Bahlis, Nizar J ^e  

^a TOM BAKER CANCER CENTRE   (Canada)

^b Faculty of Nursing   (Canada)

^c Department of Oncology ^*  (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN; INTERLEUKIN 6;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; ATTITUDE TO HEALTH; BLOOD; CANADA; CROSS-SECTIONAL STUDY; FATIGUE; FEMALE; HUMAN; IMMUNOLOGY; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; MULTIPLE MYELOMA; NURSE ATTITUDE; NURSING METHODOLOGY RESEARCH; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; RISK FACTOR; STATISTICAL MODEL;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ATTITUDE TO HEALTH; C-REACTIVE PROTEIN; CANADA; CROSS-SECTIONAL STUDIES; FATIGUE; FEMALE; HEMOGLOBINS; HUMANS; INFLAMMATION; INTERLEUKIN-6; LINEAR MODELS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NURSE'S ROLE; NURSING METHODOLOGY RESEARCH; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RISK FACTORS;

EID: 67649170585     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/09.ONF.209-216     Document Type: Article

References (54)

1. Aaronson, N.K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N.J., et al. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-376. (Pubitemid 23073154)
2. Ahlberg, K., Ekman, T., & Gaston-Johansson, F. (2004). Levels of fatigue compared to levels of cytokines and hemoglobin during pelvic radiotherapy: A pilot study. Biological Research for Nursing, 5(3), 203-210.
3. Ahlberg, K., Ekman, T., Gaston-Johansson, F., & Mock, V. (2003). Assessment and management of cancer-related fatigue in adults. Lancet, 362(9384), 640-650. (Pubitemid 37013308)
4. Alberta Cancer Board. (2004). Research protocol approval application for science and ethics. Retrieved August 10, 2004, from http://www.cancerboard.ab. ca/NR/rdonlyres/F32A2CA4-C861-4538-8786-C486C4B0DD81/0/ ResearchEthicsBoardApplicationJanuary2009.doc
5. Andrews, N.C. (2004). Anemia of inflammation: The cytokine-hepcidin link. Journal of Clinical Investigation, 113(9), 1251-1253. (Pubitemid 39069921)
6. Barnes, E.A., & Bruera, E. (2002). Fatigue in patients with advanced cancer: A review. International Journal of Gynecological Cancer, 12(5), 424-428.
7. Bataille, R., Barlogie, B., Lu, Z.Y., Rossi, J.F., Lavabre-Bertrand, T., Beck, T., et al. (1995). Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood, 86(2), 685-691.
8. Bohlius, J., Wilson, J., Seidenfeld, J., Piper, M., Schwarzer, G., Sandercock,J., et al. (2006). Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. Journal of the National Cancer Institute, 98(10), 708-714. (Pubitemid 43821788)
9. Bower, J.E., Ganz, P.A., Desmond, K.A., Rowland, J.H., Meyerowitz, B.E., & Belin, T.R. (2000). Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life. Journal of Clinical Oncology, 18(4), 743-753. (Pubitemid 30106604)
10. Brown, D.J., McMillan, D.C., & Milroy, R. (2005). The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. Cancer, 103(2), 377-382. (Pubitemid 40129298)
11. Clearfield, M.B. (2005). C-reactive protein: A new risk assessment tool for cardiovascular disease. Journal of the American Osteopathic Association, 105(9), 409-416. (Pubitemid 41603444)
12. Collado-Hidalgo, A., Bower, J.E., Ganz, P.A., Cole, S.W., & Irwin, M.R. (2006). Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clinical Cancer Research, 12(9), 2759-2766.
13. Dimeo, F., Schmittel, A., Fietz, T., Schwartz, S., Kohler, P., Boning, D., et al. (2004). Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatment. Annals of Oncology, 15(8), 1237-1242. (Pubitemid 39199311)
14. Durie, B.G., Kyle, R.A., Belch, A., Bensinger, W., Blade, J., Boccadoro, M., et al. (2003). Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematology Journal, 4(6), 379-398. (Pubitemid 38088783)
15. Gutstein, H.B. (2001). The biologic basis of fatigue. Cancer, 92(6, Suppl.), 1678-1683. (Pubitemid 32939174)
16. Hair, J.F., Anderson, R.E., Tatham, R.L., & Black, W.C. (1998). Multivariate data analysis (5th ed.). Upper Saddle River, NJ: Prentice Hall.
17. Harousseau, J.L., & Moreau, P. (2002). Prognostic factors in myeloma. In J. Mehta & S. Singhal (Eds.), Myeloma (pp. 169-183). London: Martin Dunitz.
18. Hideshima, T., Bergsagel, P.L., Kuehl, W.M., & Anderson, K.C. (2004). Advances in biology of multiple myeloma: Clinical applications. Blood, 104(3), 607-618. (Pubitemid 38970551)
19. Holzner, B., Kemmler, G., Greil, R., Kopp, M., Zeimet, A., Raderer, M., et al. (2002). The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Annals of Oncology, 13(6), 965-973. (Pubitemid 34752693)
20. Illman, J., Corringham, R., Robinson, D., Jr., Davis, H.M., Rossi, J.F., Cella, D., et al. (2005). Are inflammatory cytokines the common link between cancer-associated cachexia and depression? Journal of Supportive Oncology, 3(1), 37-50. (Pubitemid 41029582)
21. Kurzrock, R. (2001). The role of cytokines in cancer-related fatigue. Cancer, 92(6, Suppl.), 1684-1688. (Pubitemid 32939175)
22. Kyle, R.A., Gertz, M.A., Witzig, T.E., Lust, J.A., Lacy, M.Q., Dispenzieri, A., et al. (2003). Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings, 78(1), 21-33. (Pubitemid 36033957)
23. Lee, B.N., Dantzer, R., Langley, K.E., Bennett, G.J., Dougherty, P.M., Dunn, A.J., et al. (2004). A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation, 11(5), 279-292. (Pubitemid 39194326)
24. Lind, M., Vernon, C., Cruickshank, D., Wilkinson, P., Littlewood, T., Stuart, N., et al. (2002). The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. British Journal of Cancer, 86(8), 1243-1249.
25. Ludwig, H., Rai, K., Blade, J., Dammacco, F., Degos, L., Itri, L., et al. (2002). Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: Epoetin treatment recommendations. Hematology Journal, 3(3), 121-130.
26. Maccio, A., Madeddu, C., Massa, D., Mudu, M.C., Lusso, M.R., Gramignano, G., et al. (2005). Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: Role of inflammation in cancer-related anemia. Blood, 106(1), 362-367. (Pubitemid 40967214)
27. Mazhar, D., Gillmore, R., & Waxman, J. (2005). COX and cancer. QJM: An International Journal of Medicine, 98(10), 711-718. (Pubitemid 41548548)
28. Morrow, G.R., Andrews, P.L., Hickok, J.T., Roscoe, J.A., & Matteson, S. (2002). Fatigue associated with cancer and its treatment. Supportive Care in Cancer, 10(5), 389-398. (Pubitemid 36061657)
29. Morrow, G.R., Shelke, A.R., Roscoe, J.A., Hickok, J.T., & Mustian, K. (2005). Management of cancer-related fatigue. Cancer Investigation, 23(3), 229-239. (Pubitemid 40770741)
30. National Comprehensive Cancer Network. (2008). NCCN Clinical Practice Guidelines in Oncology™: Cancer-related fatigue [v.1.2008]. Retrieved January 22, 2009, from http://www.nccn.org/professionals/physician-gls/PDF/ fatigue.pdf
31. Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B.K., et al. (2004). IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. Journal of Clinical Investigation, 113(9), 1271-1276. (Pubitemid 39069926)
32. Olson, K., & Morse, J. (2005). Delineating the concept of fatigue using a pragmatic utility approach. In J. Cutcliff & H. McKenna (Eds.), The essential concepts of nursing (pp. 141-159). Oxford, England: Elsevier Science.
33. Olson, K., Tom, B., Hewitt, J., Whittingham, J., Buchanan, L., & Ganton, G. (2002). Evolving routines: Preventing fatigue associated with lung and colorectal cancer. Qualitative Health Research, 12(5), 655-670.
34. Olson, K., Turner, A.R., Courneya, K.S., Field, C., Man, G., Cree, M., et al. (2008). Possible links between behavioral and physiological indices of tiredness, fatigue, and exhaustion in advanced cancer. Supportive Care in Cancer, 16(3), 241-249. (Pubitemid 351422799)
35. Osoba, D., Aaronson, N., Zee, B., Sprangers, M., & te Velde, A. (1997). Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. Quality of Life Research, 6(2), 103-108. (Pubitemid 27207274)
36. Palumbo, A., Bertola, A., Musto, P., Caravita, T., Callea, V., Cangialosi, C., et al. (2004). A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs oral melphalan, prednisone (MP): An interim analysis. Blood, 104(11), 207.
37. Prue, G., Rankin, J., Allen, J., Gracey, J., & Cramp, F. (2006). Cancer-related fatigue: A critical appraisal. European Journal of Cancer, 42(7), 846-863.
38. Ringdal, K., Ringdal, G.I., Kaasa, S., Bjordal, K., Wisloff, F., Sundstrom, S., et al. (1999). Assessing the consistency of psychometric properties of the HRQoL scales within the EORTC QLQ-C30 across populations by means of the Mokken Scaling Model. Quality of Life Research, 8(1-2), 25-43. (Pubitemid 29362744)
39. Rivera, S., Liu, L., Nemeth, E., Gabayan, V., Sorensen, O.E., & Ganz, T. (2005). Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood, 105(4), 1797-1802. (Pubitemid 40223704)
40. Rossi, J.F., Fegueux, N., Lu, Z.Y., Legouffe, E., Exbrayat, C., Bozonnat, M.C., et al. (2005). Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140mg/m2 of melphalan in multiple myeloma: Results of a pilot study including biological aspects. Bone Marrow Transplantation, 36(9), 771-779. (Pubitemid 41613299)
41. Ryan, J.L., Carroll, J.K., Ryan, E.P., Mustian, K.M., Fiscella, K., & Morrow, G.R. (2007). Mechanisms of cancer-related fatigue. Oncologist, 12(Suppl. 1), 22-34.
42. Schubert, C., Hong, S., Natarajan, L., Mills, P.J., & Dimsdale, J.E. (2007). The association between fatigue and inflammatory marker levels in cancer patients: A quantitative review. Brain, Behavior, and Immunity, 21(4), 413-427. (Pubitemid 46528677)
43. Scott, H.R., McMillan, D.C., Forrest, L.M., Brown, D.J., McArdle, C.S., & Milroy, R. (2002). The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. British Journal of Cancer, 87(3), 264-267.
44. Sharma, S., Nemeth, E., Chen, Y.H., Goodnough, J., Huston, A., Roodman, G.D., et al. (2008). Involvement of hepcidin in the anemia of multiple myeloma. Clinical Cancer Research, 14(11), 3262-3267.
45. Trikha, M., Corringham, R., Klein, B., & Rossi, J.F. (2003). Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence. Clinical Cancer Research, 9(13), 4653-4665. (Pubitemid 37323267)
46. Turner, R., Anglin, P., Burkes, R., Couture, F., Evans, W., Goss, G., et al. (2001). Epoetin alfa in cancer patients: Evidence-based guidelines. Journal of Pain and Symptom Management, 22(5), 954-965. (Pubitemid 33111997)
47. University of Alberta. (2004). Human research-University of Alberta standards for the protection of human research participants. Retrieved January 22, 2009, from http://www.uofaweb.ualberta.ca/GFCPOLICYMANUAL/content.cfm?ID- page=37738
48. van Zaanen, H.C., Lokhorst, H.M., Aarden, L.A., Rensink, H.J., Warnaar, S.O., van der Lelie, J., et al. (1998). Chimaeric anti-interleukin-6 monoclonal antibodies in the treatment of advanced multiple myeloma: A phase I dose-escalating study. British Journal of Haematology, 102(3), 783-790. (Pubitemid 28387063)
49. Wisloff, F., Gulbrandsen, N., Hjorth, M., Lenhoff, S., & Fayers, P. (2005). Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes. European Journal of Haematology, 75(4), 293-298. (Pubitemid 41297605)
50. Wood, L.J., Nail, L.M., Gilster, A., Winters, K.A., & Elsea, C.R. (2006). Cancer chemotherapy-related symptoms: Evidence to suggest a role for proinflammatory cytokines. Oncology Nursing Forum, 33(3), 535-542. (Pubitemid 44870222)
51. Wratten, C., Kilmurray, J., Nash, S., Seldon, M., Hamilton, C.S., O'Brien, P.C., et al. (2004). Fatigue during breast radiotherapy and its relationship to biological factors. International Journal of Radiation Oncology, Biology, Physics, 59(1), 160-167. (Pubitemid 38501520)
52. Yang, J., Wezeman, M., Zhang, X., Lin, P., Wang, M., Qian, J., et al. (2007). Human C-reactive protein binds activating Fcy receptors and protects myeloma tumor cells from apoptosis. Cancer Cell, 12(3), 252-265. (Pubitemid 47333419)
53. Yellen, S.B., Cella, D.F., Webster, K., Blendowski, C., & Kaplan, E. (1997). Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. Journal of Pain and Symptom Management, 13(2), 63-74. (Pubitemid 27147321)
54. Yi, Q., Yang, J., Wezeman, M., Zhang, X., Qian, J., Hong, S., et al. (2007). C-reactive protein protects myeloma cells from apoptosis via activating ITAM-containing FcyRII. Haematologica, 92(Suppl. 2), PO-210.